CONGRESS|#EHA2021|@ThierryFacon, Lille University Hospital, presented poster on Phase3 IKEMA trial. It was identified that addition of Isatuximab to carfilzomib & dexamethasone improved PFS & quality of response in elderly pts, with a manageable safety profile #mmsm #myeloma pic.twitter.com/tHQW6XkJSh
— Multiple Myeloma Hub (@MM_Hub) June 17, 2021